AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04850001 — intervention group
Intervention type: DRUG
Intervention: Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Description: All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
Study NCT00806351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Anidulafungin
Description: Subjects in this arm will receive active anidulafungin and placebo caspofungin
Study NCT00806351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Caspofungin
Description: Subjects in this arm will receive active caspofungin and placebo anidulafungin
Study NCT04899154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool sampling
Description: Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
Study NCT04899154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool sampling
Description: Participants will provide one stool sample at inclusion
Study NCT01972568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 milligram (mg)
Description: Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
Study NCT01972568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
Study NCT01972568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
Study NCT04111198 — intervention group
Intervention type: RADIATION
Intervention: Cardiac MRI
Description: Cardiac MRI
Study NCT04340362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-147
Description: Tablets for oral administration.
Study NCT04270734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
Study NCT04270734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
Study NCT04270734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
Study NCT04270734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
Study NCT02767219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
Study NCT02767219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil
Description: Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
Study NCT02767219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
Study NCT02767219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
Study NCT00811057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 Magnesium Sulfate
Description: Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
Study NCT00811057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
Study NCT00811057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
Study NCT06409988 — intervention group
Intervention type: OTHER
Intervention: Safe discharge
Description: There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
Study NCT01752803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: mix probiotic
Study NCT01752803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00567515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure LAA Exclusion System
Description: Placement of clip of LAA.
Study NCT03319589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
Study NCT01126307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: 80 mg tid
Study NCT01126307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tid
Study NCT00612001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Study NCT00241423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
Study NCT00241423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
Study NCT02178917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback therapy
Study NCT02178917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No neurofeedback therapy
Study NCT00337818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
Study NCT03128658 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastography
Description: Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
Study NCT03128658 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computational model
Description: The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
Study NCT01199237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
Study NCT01199237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
Study NCT01199237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT01199237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT01199237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Study NCT05391724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX001
Description: single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
Study NCT01876654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruMatch® patient specific cutting guide
Study NCT00420186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
Study NCT01638884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory assessment
Description: Neuropsychological tests including clinical and original tests to compare differences between each populations
Study NCT01638884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural MRI
Description: to compare differences between each populations
Study NCT01638884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: to compare differences between each populations
Study NCT01638884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality / Memory assessment
Description: to compare differences between each populations
Study NCT01623349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 and Olaparib
Description: Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
Study NCT01623349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 and Olaparib
Description: Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
Study NCT01694628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIMB (COPD Lifestyle, Mood, and Behavior)
Description: Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
Study NCT01883323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: i.v., 25mg/m2 per day for 5 days
Study NCT01883323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes
Description: i.v., 1x10\^10 - 1.6x10\^11 cells
Study NCT01883323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-Dose Interleukin
Description: i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
Study NCT03112902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance
Description: Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
Study NCT01814800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RI-002
Description: Immune Globulin Intravenous (IGIV)
Study NCT02703740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dermal filler with lidocaine 0.3%
Description: injection in labial fold of a dermal filler
Study NCT02083991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon
Study NCT02083991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon
Study NCT04917835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLADUO(PX1000)
Description: Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
Study NCT01060735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
Study NCT02130427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Weekly 3D/4D CT scan
Study NCT02202031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Respiration
Description: Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
Study NCT02202031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
Study NCT03326219 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clarivein
Description: The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
Study NCT04369430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290
Study NCT04369430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study NCT01589068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
Study NCT01589068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
Study NCT00819624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interactive Voice Response System (IVRS)
Description: Telephone based system
Study NCT00819624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Personal Digital Assisstant (PDA)
Description: Electronic Hand Held diary
Study NCT01606592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Description: Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
Study NCT01606592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Description: Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
Study NCT01606592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting-list
Description: Sparse telephone contact during 12 weeks, then re-randomization
Study NCT00798213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
Study NCT00798213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemtuzumab ozogamicin
Description: Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
Study NCT02742870 — intervention group
Intervention type: OTHER
Intervention: Correlation of MRI results with clinical characteristics of the adnexal mass
Description: Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up.
Study NCT02047513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perioperative nab-paclitaxel/gemcitabine
Description: 2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
Study NCT02047513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant nab-paclitaxel/gemcitabine
Description: Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
Study NCT03235570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib at the protocol-defined dose administered once daily.
Study NCT04436224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
Study NCT04436224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
Study NCT04436224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol
Description: Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
Study NCT03075462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib either at 40,60,80mg twice daily,capsule oral.
Study NCT03075462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib at 250mg once daily, tablet oral
Study NCT02641236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin-polymyxin B
Study NCT03868007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC
Description: The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT03868007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-RIC
Description: The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
Study NCT00069576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional counseling
Study NCT00069576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self blood glucose monitoring
Study NCT02304536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH
Description: 70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day